🤼 What are the expected completion dates for these clinical trials?

The expected completion dates for Cellectar's CLOVER-2 Phase 1 Clinical Trial and CLOVER-WaM Phase 2 Clinical Trial are not explicitly stated. However, we can infer the following:

1. **CLOVER-2 Phase 1 Clinical Trial**: The initial results for the CLOVER-2 Phase 1 clinical trial were announced on June 11, 2025. Since the trial is ongoing and has not yet completed, it is difficult to determine an exact completion date. However, the company's announcement of initial results suggests that the trial has been ongoing for at least several months and is likely to continue until all planned cohorts have been completed and follow-up evaluations are finished.
2. **CLOVER-WaM Phase 2 Clinical Trial**: The CLOVER-WaM Phase 2 clinical trial has reported its results, with an 83.6% overall response rate (ORR) and has exceeded primary and secondary efficacy endpoints. Since the trial has already reported its results, it can be inferred that the trial is completed, and the focus is now on regulatory approvals and market preparations.

It's important to note that clinical trials can take varying lengths of time, depending on factors such as the complexity of the study design, the number of patients enrolled, and the pace of data collection and analysis. While we can't pinpoint exact completion dates, Cellectar Biosciences is actively engaged in navigating the regulatory review processes and seeking guidance from agencies like the FDA and EMA, which suggests that the company is committed to bringing iopofosine I-131 to market as soon as possible.